Amyris Inc. (“Amyris”) is a leading synthetic biology and consumer products company headquartered in Emeryville, CA. Through proprietary technology, cell programming, and the fermentation of sugar and yeast, Amyris successfully developed one of the largest global libraries of clean, sustainable ingredients and a portfolio of beauty and personal care brands. Amyris’s generated revenue through two main segments: (1) Consumer and (2) Technology Access. The Consumer segment was comprised of seven operating beauty care and wellness brands and the Technology Access segment delivered high-performing, sustainable molecules as ingredients to industry leaders across end-markets.
Intrepid Investment Bankers was retained as the exclusive investment banker to Amyris to sell its consumer brands portfolio through a Chapter 11 section 363 sale process. Intrepid ran a robust sale process for the consumer brands and was able to successfully close the sale of all 7 consumer brands (Biossance, JVN, Rose Inc., MenoLabs, Stripes, Pipette, and 4U by Tia). Furthermore, in support of the Plan of Reorganization, Intrepid also ran a sale process for the Technology Access assets and provided the expert testimony in support of the Plan. Following the sale of the consumer brands and completion of the required Plan milestones, Amyris emerge from Chapter 11 in February 2024 with a clear focus in the future of its technology and R&D assets.